UNSPSC 51321806: Clofibride

This classification denotes an anti-lipidemic agent with the molecular formula C16H22ClNO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0S9SLS3L93, chemically known as 4-chlorophenoxy isopropionyl 4-hydroxy-n,n-dimethylbutyramide but generally known as clofibride, which bears US NIH Compound Identifier 160134. European Medicines Agency schedules Clofibride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06708MIG.

UNSPSC 51321806 Clofibride, a Commodity code, encompasses pharmaceutical products that state and local governments procure for emergency medical services, health benefit programs, and institutional healthcare delivery. Based on recent solicitations, the code captures individual medication line items supplied to fire departments, EMS systems, and state health agencies—notably including emergency medications like epinephrine, labetalol, adenosine, and diltiazem, as well as generic pharmaceuticals distributed through state cooperative purchasing networks. Issuing bodies include city purchasing departments (fire rescue services), state health agencies, and multistate cooperative purchasing alliances. The City of Tampa and the Texas Health and Human Services Commission represent the range of end-user demand, from tactical EMS supply procurement to statewide pharmacy benefit program design.

Recent activity spans Florida, Texas, and the Upper Midwest through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), with secondary participation from Oregon through MMCAP's network. The City of Tampa issued IFB 26-P-00188 for Advanced Life Support Medications on April 24, 2026, seeking 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials for Tampa Fire Rescue with a response deadline of April 8, 2026 and estimated contract value of $40,000; the procurement includes a 5 percent bid discount for Small Local Business Enterprise participation. The Minnesota Department of Administration issued RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products on January 20, 2026 with a March 26, 2026 response deadline, requiring manufacturers to supply through AmerisourceBergen, Cardinal Health, and Morris & Dickson with contracts effective July 1, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program before issuing formal procurement.